Ginkgo Bioworks (DNA) Competitors $13.20 -0.33 (-2.40%) Closing price 03:59 PM EasternExtended Trading$13.41 +0.22 (+1.63%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TLX, ADMA, AMRX, INDV, CNTA, APLS, XENE, GMTX, RARE, and CGONShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), AMNEAL PHARMACEUTICALS (AMRX), Indivior (INDV), Centessa Pharmaceuticals (CNTA), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Telix Pharmaceuticals ADMA Biologics AMNEAL PHARMACEUTICALS Indivior Centessa Pharmaceuticals Apellis Pharmaceuticals Xenon Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical CG Oncology Telix Pharmaceuticals (NASDAQ:TLX) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Does the media refer more to TLX or DNA? In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for Telix Pharmaceuticals and 5 mentions for Ginkgo Bioworks. Telix Pharmaceuticals' average media sentiment score of 0.74 beat Ginkgo Bioworks' score of 0.28 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in TLX or DNA? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer TLX or DNA? Telix Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 120.13%. Ginkgo Bioworks has a consensus target price of $9.00, indicating a potential downside of 31.79%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Telix Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Is TLX or DNA more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -136.56%. Telix Pharmaceuticals' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Ginkgo Bioworks -136.56%-43.25%-22.29% Which has better earnings and valuation, TLX or DNA? Telix Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M6.25$32.93MN/AN/AGinkgo Bioworks$230.82M3.38-$547.03M-$5.86-2.25 SummaryTelix Pharmaceuticals beats Ginkgo Bioworks on 12 of the 14 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$800.38M$3.36B$6.05B$21.49BDividend YieldN/A2.31%5.73%3.67%P/E Ratio-2.2522.0885.3129.66Price / Sales3.38478.69601.4686.41Price / CashN/A44.9825.7717.79Price / Book1.0010.3812.674.63Net Income-$547.03M-$52.47M$3.32B$1.01B7 Day Performance-11.26%0.59%-0.44%-1.84%1 Month Performance31.69%13.95%8.72%0.55%1 Year Performance80.01%29.25%75.69%13.45% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.1734 of 5 stars$13.20-2.4%$9.00-31.8%+84.4%$800.38M$230.82M-2.25640Gap UpTLXTelix Pharmaceuticals4.2243 of 5 stars$10.18-1.0%$21.00+106.3%N/A$3.45B$516.72M0.00N/AGap DownADMAADMA Biologics3.4849 of 5 stars$14.07-4.0%$27.67+96.6%-15.2%$3.36B$474.17M16.36530AMRXAMNEAL PHARMACEUTICALS3.2411 of 5 stars$10.55+1.5%$12.00+13.7%+16.3%$3.31B$2.79B1,056.068,100INDVIndivior3.2317 of 5 stars$22.73-1.9%$22.00-3.2%+218.8%$3.13B$1.17B36.661,051CNTACentessa Pharmaceuticals2.7694 of 5 stars$23.00-1.0%$32.38+40.8%+39.5%$3.08B$6.85M-12.85200Analyst UpgradeAPLSApellis Pharmaceuticals4.1524 of 5 stars$24.36+2.4%$33.29+36.7%-7.3%$3.08B$781.37M-13.38770XENEXenon Pharmaceuticals2.455 of 5 stars$39.55-0.2%$53.30+34.8%-3.8%$3.05B$9.43M-11.14210GMTXGemini TherapeuticsN/A$67.78+2.9%N/A+46.4%$2.94BN/A-67.7830RAREUltragenyx Pharmaceutical4.3509 of 5 stars$30.19-3.3%$81.50+170.0%-42.9%$2.91B$560.23M-5.461,294CGONCG Oncology2.1636 of 5 stars$38.13-4.2%$56.55+48.3%+19.8%$2.91B$1.14M-21.5461Insider Trade Related Companies and Tools Related Companies Telix Pharmaceuticals Competitors ADMA Biologics Competitors AMNEAL PHARMACEUTICALS Competitors Indivior Competitors Centessa Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Gemini Therapeutics Competitors Ultragenyx Pharmaceutical Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
